Can BK virus PCR be a Surrogate Marker in Kidney Transplant Recipients?: A systematic review and meta-analysis

> Aasith Villavicencio M.D. Yosuke Ebisu M.D. Veronica Miller PhD John Reynolds Hannah Imlay M.D. Ajit Limaye M.D. Yoichiro Natori M.D., M.P.H. **J**Health Jackson

Background

- Drs. Imlay and Limaye's group provided the new definition for BK nephropathy in kidney transplant recipients (Imlay et al. CID 2022)
- BK PCR testing has not been well defined as a surrogate marker for BK nephropathy
- <u>Aim</u>: Assess the available global literature to determine whether BK levels in blood or urine correlate with BK nephropathy in kidney transplant recipients

JHealth Jackson

Research questions

- Does BK DNAemia correlate with BK nephropathy?
 - Does high-level BK DNAemia correlate with BK nephropathy?
- Does BK DNAuria correlate with BK nephropathy?
 - Does high-level BK DNAuria correlate with BK nephropathy?
- Does decreasing levels of BK viremia correlate with reducing or preventing BK nephropathy?
- Does decreasing levels of BK viuria correlate with reducing or preventing BK nephropathy?
- Is improvement of BK nephropathy findings (with serial biopsy) correlated with BK viral load reduction (in blood and/or urine)?

in kidney transplant recipients

JHealth Jackson

Inclusion criteria

- Population Kidney transplant recipients of any age
- Intervention BK DNAemia or DNAuria after transplantation
- Comparison No BK DNAemia or DNAuria after transplantation
- Outcomes BKVAN as defined by the study and BKVAN proven by biopsy
- Timing Any time from transplant to outcomes evaluation
- Study design Observational clinical studies, randomized controlled trials, case series if >10 cases; conference proceedings if data was sufficient

Additionally, studies on **follow-up biopsies** after BKVAN diagnosis with serial BK VL measurements – to assess for improvement of BKVAN findings with BK VL reduction

JHealth Jackson

Exclusion criteria

Poster/conference abstract/letters with insufficient data, case report/study, reviews, editorials, opinion articles without original data



Animal studies

ğ

No measurement of quantitative polymerase chain reaction (PCR) eg. antigenemia, mRNA, qualitative PCR



Only laboratory data without clinical information





- Search engines: Medline, Embase, Scopus, Web of Science, CINAHL Plus with Full Text
- Software: COVIDENCE
- Search terms:
 - Kidney
 - Transplant(s), Graft, Allograft(s), Allotransplant, Autograft, Transplant recipients; Organ transplantation; Transplantation, autologous; Transplantation, heterotopic; Transplantation, homologous
 - BK virus, BKV, BKPyV, polyomavirus, polyomavirus infections
 - Viremia, viraemia, viral load, virus load, viral burden, virus burden, virus titer, virus titre, viral titer, viral threshold, DNAemia, Viruria, viruria
- Preliminary search: August 2019
- Updated search: January 2023





RESULTS

JHealth Jackson



PRISMA diagram

Identification

Included

Does BK viremia correlate with BKVAN (any definition)?

24% (95% CI 0.17 – 0.30)



Miami Transplant Institute

JHealth

BKVAN (biopsy-confirmed) prevalence among those with BK viremia

Does BK viremia correlate with biopsyproven BKVAN?

20% (95% CI 0.16 – 0.24)



Miami Transplant Institute

JHealth

BKVAN (any definition) prevalence among those with high BK viremia





Miami Transplant Institute

BKVAN (biopsy-confirmed) prevalence among those with high BK viremia

Does high-level BK viremia correlate with biopsy-proven BKVAN?

35% (95% CI 0.22 – 0.49)



JHealth Jackson

BKVAN (any definition) prevalence among those with BK viruria

Does BK DNAuria correlate with BKVAN (any definition)?

14% (95% CI 0.08 – 0.21)

| | | | | | % |
|-----------------------|------------|-------|-------------------|-----------------|--------|
| Study | BKV(+) | BKVAN | E | S (95% CI) | Weight |
| Ginevri 2003 | 26 | 3 | <mark>_</mark> 0. | 12 (0.02, 0.30) | 7.24 |
| Costa 2008 | 19 | 3 | 0. | 16 (0.03, 0.40) | 6.43 |
| Sung 2008 | 18 | 8 | 0. | 44 (0.22, 0.69) | 6.28 |
| Wu 2008 | 51 | 3 | | 06 (0.01, 0.16) | 8.75 |
| Astegiano 2011 | 54 | 2 | ─ 0. | 04 (0.00, 0.13) | 8.85 |
| Badwal 2011 | 26 | 5 | 0. | 19 (0.07, 0.39) | 7.24 |
| Naumnik 2011 | 37 | 1 | ■ 0. | 03 (0.00, 0.14) | 8.08 |
| Mindlova 2012 | 28 | 2 | | 07 (0.01, 0.24) | 7.43 |
| Saundh 2013 | 37 | 2 | | 05 (0.01, 0.18) | 8.08 |
| Teutsch 2015 | 40 | 10 | 0. | 25 (0.13, 0.41) | 8.25 |
| El Ansary 2016 | 11 | 3 | | 27 (0.06, 0.61) | 4.95 |
| Schwarz 2016 | 85 | 22 | 0. | 26 (0.17, 0.37) | 9.59 |
| Skulratanasak 2018 | 53 | 11 | 0. | 21 (0.11, 0.34) | 8.82 |
| Overall (I^2 = 71.819 | %, p = 0.0 | 0) | 0. | 14 (0.08, 0.21) | 100.00 |
| Overall (I^2 = 71.819 | %, p = 0.0 | 0) | 0. | 14 (0.08, 0.21) | 100.0 |
| | | |) .25 .5 .75 1 | | |

BKVAN (biopsy-confirmed) prevalence among those with BK viruria

% BKVAN ES (95% CI) Weight Study BKV(+) Ginevri 2003 26 3 0.12 (0.02, 0.30) 7.92 **Does BK DNAuria** Costa 2008 0.16 (0.03, 0.40) 3 7.08 19 Sung 2008 18 8 0.44 (0.22, 0.69) 6.93 correlate with Wu 2008 51 3 0.06 (0.01, 0.16) 9.44 Astegiano 2011 54 2 0.04 (0.00, 0.13) 9.55 biopsy-proven Badwal 2011 26 5 0.19 (0.07, 0.39) 7.92 Naumnik 2011 37 0.03 (0.00, 0.14) 1 8.78 **BKVAN**? Mindlova 2012 0.04 (0.00, 0.18) 28 1 8.11 Teutsch 2015 10 0.25 (0.13, 0.41) 40 8.95 0.27 (0.06, 0.61) El Ansary 2016 11 3 5.53 15% Schwarz 2016 85 22 0.26 (0.17, 0.37) 10.28 Skulratanasak 2018 11 0.21 (0.11, 0.34) 9.52 53 (95% CI 0.08 - 0.22)Overall (l² = 73.68%, p = 0.00) 0.15 (0.08, 0.22) 100.00 .75 .25 .5 Proportion **J**Health Jackson

Does decreasing levels of BK DNAemia correlate with reducing or preventing BKVAN?

- Several studies documented the correlation between BKV DNAemia clearance and BKVAN prevention (Almeras 2007, Bennet 2010, Elfadawy 2014, Brennan 2005, Chung 2012)
- Some studies also showed prolonged/persistent BK DNAemia was associated with BKVAN (Bagchi 2017, Chan 2019, Elfadawy 2014, Huang 2015, Jacobi 2013, Reischig 2019)

JHealth Jackson

Almeras et al. (Clinical Transplantation 2007)

- Patients without BKVAN on initial biopsy (11): after reduction of IS in patients without BKVN, viremia disappeared in 8 of 11, decreased in 2 of 11, and increased in 1 patient who eventually developed BKVAN
- Patients with BKVAN (2): viremia remained positive in 1 patient and disappeared in the second, but renal function deteriorated in both



Health Jackson

Elfadawy (CJASN 2014)

- The incidence of BKVAN was limited to the persistent high viremia group (1.3%, P<0.001).
- Significant difference in graft rejection rates: 21.5% in nonviremia, 17.3% in persistent low viremia, 19% in transient low viremia, 34% in persistent high viremia, and 50% in transient high viremia.



JHealth Jackson

Does decreasing levels of BK DNAuria correlate with reducing or preventing BKVAN?

- Boobes 2015: 17 patients with DNAuria treated by reduction of immunosuppression, all of them cleared DNAuria. None of them developed BKVAN.
- Bennet 2010: 34 patients with DNAuria. No BKVAN was observed after reducing mycophenolate (surveillance biopsies)



Is improvement of BK nephropathy findings (with serial biopsy) correlated with BK viral load reduction (in blood and/or urine)?



8 studies



Persistent high BKV DNAemia correlated with increased risk of graft loss



Correlation between viral load clearance and improvement of pathology findings in serial biopsies

JHealth Jackson

Omic (Frontiers in Medicine 2021)

- Follow-up period of 24 months after biopsy
- Multivariable regression model: absolute viral load change was a significant risk factor for graft survival
 each log unit drop in absolute viral load decreased the risk for graft loss by 22%.



FIGURE 4 | Heat map of BANFF single lesions in the index biopsy in relation to absolute viral load; shows the mean value of BANFF scores (color scaled) at the index biopsy according to the viral load at the time of the diagnosis, (copies/ml), h, arteriolar hyalinosis; g, glomerulitis; i, interstitial inflammation; v, intimal arteritis; t, tubulitis; cg, transplant glomerulopathy; ci, interstitial fibrosis; ct, tubular atrophy; cv, arterial fibrous intimal thickening, color scale describes the mean score of each group.

JHealth Jackson

Is improvement of BK nephropathy findings (with serial biopsy) correlated with BK viral load reduction (in blood and/or urine)?

- Drachenberg et al. (AJT 2004) n=121/158 biopsies, US
 - 2/11 patients with interstitial fibrosis & tubular atrophy had increased VL \rightarrow graft loss
- Drachenberg et al. (AJT 2017) n=71/206 biopsies, US
 - 76% (54/71) overall, and 80% (48/60) of the patients with functioning grafts cleared viremia (mean 28.2 \pm 21.9 weeks after BKVAN diagnosis)
 - 6/6 patients with decreasing VL showed no BKVAN in the second biopsy
 - Poor viral clearance in 8/11 patients with graft loss
 - No clear correlation between pathology and viral clearance but easier identification of H&E cytopathic changes in 5 patients with increasing viremia

JHealth Jackson

Nankivell et al. (AJT 2017) n=63 kidney Tx with BKVAN, 453 biopsies, Australia



Limitations

HETEROGENEOUS STUDIES

- Studies included were published before the new definition paper different definitions of BKVAN
- Different definitions of BKVAN proven by biopsy
- Different PCR methods (eg primer)

JHealth Jackson

• •

Any questions?

Miami

Institute

Transplant